Loading...
Market
Will PS757 be licensed by a major pharmaceutical company by August 5, 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Official press releases from the research team or pharmaceutical companies
Story
New Compound PS757 Fights Drug-Resistant Bacteria, Guides GmPcide Development
Aug 5, 2024, 07:05 AM
Researchers have discovered a new compound, PS757, that shows promise in fighting flesh-eating and other drug-resistant bacteria. This revolutionary dual-action antibiotic makes bacterial resistance nearly impossible by damaging the cell membranes of the bacteria. The findings, which were tested on Gram-positive pathogens in mice, are expected to guide the development and optimization of a new class of antibiotics called GmPcide compounds. The discovery was announced on August 4 and further detailed on August 5.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Johnson & Johnson • 25%
Merck • 25%
AstraZeneca • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Pfizer • 25%
AstraZeneca • 25%
GlaxoSmithKline • 25%
Other • 25%